How is Aklief (tazarotene 0.05% cream) used for acne vulgaris?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Aklief (Trifarotene 0.005% Cream) for Acne Vulgaris

Apply Aklief (trifarotene 0.005% cream) once daily in the evening as a thin layer to affected areas of the face and/or trunk on clean, dry skin, starting with one pump actuation for the face and adjusting coverage as needed for truncal acne. 1

Dosing Algorithm

Facial acne:

  • Use one pump actuation to cover the entire face (forehead, cheeks, nose, and chin) 1

Truncal acne:

  • Two pump actuations for upper trunk (reachable upper back, shoulders, chest)
  • One additional pump actuation for middle and lower back if acne is present 1

Application technique:

  • Apply in the evening only
  • Skin must be clean and dry
  • Use a thin layer only
  • Avoid eyes, lips, paranasal creases, and mucous membranes 1

Patient Age Requirements

Approved for patients ≥9 years of age 1

This is notably younger than traditional tazarotene formulations (0.05% and 0.1%), which have not established safety and efficacy in patients with acne <12 years of age 2. Aklief represents a newer-generation retinoid (trifarotene) with a different safety profile than older tazarotene formulations.

Essential Supportive Care

Start moisturizer immediately from day one of treatment 1

This is critical—do not wait for irritation to develop. The FDA label explicitly recommends moisturizer use "as frequently as needed from the initiation of treatment" 1. Maximum severity of irritation typically occurs within the first 4 weeks 1.

Managing Irritation

If patients develop erythema, scaling, dryness, or stinging/burning:

  1. Continue moisturizer (increase frequency)
  2. Reduce application frequency (alternate days)
  3. Temporarily suspend if reactions are severe
  4. Discontinue only if severe reactions persist despite modifications 1

Most adverse events (83-98%) are mild to moderate 3, and severity typically decreases with continued use 1.

Critical Safety Precautions

Pregnancy status: Category X contraindication 2

Unlike Aklief's specific FDA label which lists "None" for contraindications 1, traditional tazarotene formulations are absolutely contraindicated in pregnancy 2. While the Aklief label doesn't explicitly state pregnancy category, all retinoids carry teratogenic risk and pregnancy should be ruled out before initiating treatment.

Sun protection is mandatory:

  • Minimize exposure to sunlight and sunlamps
  • Use sunscreen products over treated areas
  • Wear protective clothing when exposure cannot be avoided
  • Weather extremes (wind, cold) may increase irritation 1

Avoid on compromised skin:

  • Do not apply to cuts, abrasions, eczematous skin, or sunburned skin
  • Avoid "waxing" as a depilatory method on treated skin 1

Clinical Context and Positioning

Topical retinoids are the core of topical acne therapy because they are comedolytic, resolve microcomedone precursor lesions, and are anti-inflammatory 2. They enhance any topical acne regimen and allow maintenance of clearance after discontinuing oral therapy 2.

Aklief (trifarotene) is a fourth-generation retinoid that selectively targets retinoic acid receptor-gamma (RAR-γ), which is the predominant RAR in the skin 4. This selective binding may contribute to its efficacy profile.

The 2024 AAD guidelines make a strong recommendation for topical retinoids in acne management 4, and combining topical therapies with multiple mechanisms of action is recommended as good practice 4.

Combination Therapy Considerations

Compatible combinations:

  • Benzoyl peroxide (use at different times of day to avoid potential oxidation)
  • Topical antibiotics (clindamycin)
  • Oral antibiotics when indicated 4

Avoid concurrent use with:

  • Other potentially irritating topical products (use with caution)
  • Keratolytic agents
  • Photosensitizing agents 2

Expected Timeline

Efficacy typically becomes apparent within 4-12 weeks of consistent use 1, 3. In clinical trials with traditional tazarotene formulations, median percentage changes in lesion counts showed significant improvement by week 12 3.

Common Pitfall to Avoid

Do not discontinue prematurely due to initial irritation. The first 4 weeks typically show maximum irritation severity, which then decreases with continued use 1. Proper moisturizer use from day one and patient education about this expected timeline prevents unnecessary discontinuation.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.